Pharmacyclics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
800 Ridgeview Dr, Horsham, Pennsylvania,...Website
www.imbruvica.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pharmacyclics
Pharmacyclics LLC is a company that operates in the Pharmaceuticals industry. It employs 1to4 people and has 500Kto1M of revenue. The company is headquartered in Horsham, Pennsylvania.Explore more
Popular SearchesPharmacyclics LLCImbruvicaSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharmacyclics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pharmacyclics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Pharmacyclics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Pharmacyclics
Earning: See what the market has to say on Pharmacyclics recently announced quarterly report
Click to see if Pharmacyclics had a recent Job posting/layoffs
Product Launch: Get notified when Pharmacyclics launches new products
Check if Pharmacyclics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Pharmacyclics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Pharmacyclics
Compare insights from companies similar to Pharmacyclics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Pharmacyclics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pharmacyclics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pharmacyclics.
Pharmacyclics Tech Stack
A closer look at the technologies used by Pharmacyclics
See more technologies
Pharmacyclics News & Media
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab...CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., June 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax), an all-oral, once-daily, chemotherapy-free,...Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., June 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic...IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
RARITAN, N.J., May 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pharmacyclics
Sign Up For FreeTo access detailed company insights
Pharmacyclics LLC is a company that operates in the Pharmaceuticals industry. It employs 1to4 people and has 500Kto1M of revenue. The company is headquartered in Horsham, Pennsylvania.... Read More
